Actos, a drug meant to treat diabetes by curtailing the body’s resistance to insulin, might increase a patient’s risk of incurring bladder cancer if taken for a long period of time. That finding comes from the University of Pennsylvania’s Perelman School of Medicine, who looked at about 60,000 patients, some taking a thiazolidinedione (TZD) like Actos and some taking a sulfonylurea drug. Out of 100,000 patients, 170 TZD patients are estimated to get bladder cancer after half a decade, compared with only 60 for sulfonylurea patients.
For more about this finding, click here.